Brain-computer interface firm raises $250m for US rollout
Precision Neuroscience has raised $250m to expand its brain-computer interface, taking total funding to $430m since the company was founded in 2021.
The company’s Layer 7 Cortical Interface is designed to sit on the surface of the brain rather than penetrate its tissue, recording electrical activity that can then be decoded into intended movement.
The aim is to give people with paralysis or conditions such as motor neurone disease a way to control digital devices or communicate through thought alone, a field of growing interest to clinicians working in neurorehabilitation.
Michael Mager, co-founder and chief executive of Precision Neuroscience, said the company had “built the clinical network, regulatory position, and manufacturing base that leadership in this field requires.”
He added that the company was “putting safety at the centre of our product design, forming deep partnerships with the world’s leading neurosurgeons and academic medical centres.”
Since its founding, the company has built a clinical footprint in BCI, with more than 100 patient procedures across 18 medical institutions, alongside FDA clearance in April 2025 for its Layer 7 cortical interface, a commercial partnership with Medtronic, and a wholly owned manufacturing facility in Texas.
The Layer 7 array is a thin, flexible electrode array designed to conform to the brain’s surface without penetrating tissue, and its FDA clearance covers implantation durations of up to 30 days.
That existing clearance is an important regulatory milestone, although it should not be interpreted as establishing approval for every potential future clinical application of the technology.
Moving to longer-duration implantation, including a system patients could eventually wear at home rather than in a hospital recovery room, will require a more demanding FDA pathway.
The company’s clinical network includes the Perelman School of Medicine at the University of Pennsylvania, University of Chicago Medicine, Mount Sinai Health System and West Virginia University’s Rockefeller Neuroscience Institute.
Its device has also been used in a commercial partnership with Medtronic, giving it access to an established neurosurgical platform.
Researchers at the University of Pennsylvania have used recordings from Layer 7 to develop a more detailed map of the human motor cortex.
The company says its system has demonstrated high-resolution recording across 4,096 electrodes and real-time decoding of intended movement, a capacity built from combining multiple 1,024-electrode arrays.
The round was co-led by Pershing Square, the Ackman Oxman Institute, and an undisclosed leading life sciences investment fund, with participation from the Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures and JSL Health Capital, among others.
Bill Ackman, chief executive of Pershing Square and co-founder of the Ackman Oxman Institute, said: “We have learned that the brain can recover from even catastrophic injury, and that there is far more that can be done for people living with neurological injuries.”
